Clinical Trials Directory

Trials / Unknown

UnknownNCT02603302

Radiation Dose Escalation in Locally Advanced Rectal Cancer

Phase II Study of Neoadjuvant Radiotherapy Dose Escalation in Association With Chemotherapy for the Treatment of Locally Advanced Rectal Cancer

Status
Unknown
Phase
Phase 2
Study type
Interventional
Enrollment
48 (estimated)
Sponsor
University of Brasilia · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

This is a one arm study where patients with locally advanced rectal cancer will receive neoadjuvant treatment with escalated dose radiotherapy (with 3D conformal radiotherapy, up to 59,4 Gy) and radiosensitizing chemotherapy. Then, patients will operated (total mesorectal excision) after 8 weeks of interval. Primary endpoint will be pCR (pathologic complete response).

Detailed description

Introduction: Rectal cancer is a highly prevalent disease all over the world. In Brazil, it is the second most common cancer among women (after breast tumors), with an estimated incidence of 17.2 cases per 100,000 inhabitants and is the third most common cancer in men (after prostate and lung cancers), with an estimated incidence of 15.4 cases per 100,000 inhabitants. Goals: The aim of this study is to evaluate the pathologic complete response (pCR) of patients with locally advanced rectal cancer (LARC) treated with neoadjuvant radiochemotherapy (RCT) employing anticancer drugs at standard dose and interval extended to surgery with or without adjuvant neoplastic therapy. Procedures: Neoadjuvant chemoradiotherapy with radiation dose escalation associated with radiosensitizing therapy and surgery with a total mesorectal excision (TME), 8 weeks after completing neoadjuvant treatment.

Conditions

Interventions

TypeNameDescription
RADIATIONDose Escalation RadiotherapyRT (3D conformal RT) 45 Gy to the whole pelvis + boost 14.4 Gy to the GTV Chemotherapy with 5-FU
PROCEDUREDelayed surgerySurgery after 8 weeks with TME (total mesorectal excision)

Timeline

Start date
2016-01-01
Primary completion
2017-12-01
Completion
2018-12-01
First posted
2015-11-11
Last updated
2016-06-14

Locations

1 site across 1 country: Brazil

Source: ClinicalTrials.gov record NCT02603302. Inclusion in this directory is not an endorsement.